Tiziana Reports Data Indicating Significant Immunomodulation effects on Immune and Inflammatory Biomarkers with Nasally Administered Foralumab in Healthy Volunteers

NEXT STORY
Orion’s Virtual Capital Markets Day today at 13.00 EEST – presentation material now available
PREV STORY
OSE Immunotherapeutics Announces Dosing of the First Healthy Volunteer in Phase 1 Clinical Trial of its Multi-Variant Second-Generation COVID-19 Vaccine
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Oncobiologics Issues Remaining Senior Secured Notes and Warrants – Raising an Aggregate $10.0 Million

CRANBURY, N.J., Jan. 10, 2017 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS) today announced that ...

author_avatar
NASDAQ Market News

Leap Therapeutics to Present at Two Investor Conferences in April

CAMBRIDGE, Mass., March 29, 2017 (GLOBE NEWSWIRE) -- Leap Therapeutics, Inc. (Nasdaq:LPTX), a biotechnology ...

author_avatar
NASDAQ Market News

Syapse Launches Precision Medicine Council to Advance Health System Adoption of Precision Oncology

A group of the nation’s leading health systems will share best practices and strategies ...

author_avatar
NASDAQ Market News